Artificial Bone Graft Substitutes for Curettage of Benign and Low-Grade Malignant Bone Tumors: Clinical and Radiological Experience with Cerasorb.
ABGS
Artificial bone graft substitutes
Bone tumors
Curettage
Journal
Indian journal of orthopaedics
ISSN: 0019-5413
Titre abrégé: Indian J Orthop
Pays: Switzerland
ID NLM: 0137736
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
24
02
2023
accepted:
30
05
2023
medline:
23
8
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
epublish
Résumé
Artificial bone graft substitutes (ABGS) for curettage of bone tumors are becoming increasingly popular. The aim of this retrospective analysis was to determine the efficacy of the ABGS Cerasorb (Curasan-AG, Kleinostheim, Germany), a beta-tricalcium phosphate (beta-TCP), concerning resorption profile, bone healing, and remodeling after surgery and to evaluate potential complications. Forty-three patients suffering from benign and low-grade malignant bone tumors were treated with curettage and refilling of the bony cavity using the ABGS Cerasorb between 2018 and 2021 and included in the final analysis. Clinical follow-up exams with X-rays in two planes were performed 6 weeks, 3 months, 6 months, and 1 year after surgery. After a mean follow-up period of 14.6 months, radiological consolidation following curettage was observed in all patients. Total resorption was observed in 16.3% of patients; in the other 83.7%, resorption was partial. In four patients, of whom two had a tumor in the distal femur and two in the humeral diaphysis, fractures occurred within 6 weeks after primary surgery. In conclusion, the beta-TCP Cerasorb seems to be a reliable bone graft substitute with low complication rates and is a suitable alternative to autologous bone grafts or allografts. Nonetheless, it shows a tendency of delayed resorption. III; retrospective cohort study.
Sections du résumé
Background
UNASSIGNED
Artificial bone graft substitutes (ABGS) for curettage of bone tumors are becoming increasingly popular. The aim of this retrospective analysis was to determine the efficacy of the ABGS Cerasorb (Curasan-AG, Kleinostheim, Germany), a beta-tricalcium phosphate (beta-TCP), concerning resorption profile, bone healing, and remodeling after surgery and to evaluate potential complications.
Methods
UNASSIGNED
Forty-three patients suffering from benign and low-grade malignant bone tumors were treated with curettage and refilling of the bony cavity using the ABGS Cerasorb between 2018 and 2021 and included in the final analysis. Clinical follow-up exams with X-rays in two planes were performed 6 weeks, 3 months, 6 months, and 1 year after surgery.
Results
UNASSIGNED
After a mean follow-up period of 14.6 months, radiological consolidation following curettage was observed in all patients. Total resorption was observed in 16.3% of patients; in the other 83.7%, resorption was partial. In four patients, of whom two had a tumor in the distal femur and two in the humeral diaphysis, fractures occurred within 6 weeks after primary surgery.
Conclusion
UNASSIGNED
In conclusion, the beta-TCP Cerasorb seems to be a reliable bone graft substitute with low complication rates and is a suitable alternative to autologous bone grafts or allografts. Nonetheless, it shows a tendency of delayed resorption.
Level of Evidence
UNASSIGNED
III; retrospective cohort study.
Identifiants
pubmed: 37609019
doi: 10.1007/s43465-023-00919-1
pii: 919
pmc: PMC10441831
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1409-1414Informations de copyright
© The Author(s) 2023.
Déclaration de conflit d'intérêts
Conflict of interestThe authors have no relevant financial or non-financial interests to disclose.
Références
Orthopedics. 2004 Jan;27(1 Suppl):s131-5
pubmed: 14763545
Biomaterials. 2002 Dec;23(23):4523-31
pubmed: 12322972
Int Orthop. 2006 Dec;30(6):510-3
pubmed: 16736145
Biomaterials. 2005 Apr;26(12):1445-51
pubmed: 15482833
Clin Orthop Relat Res. 2014 Mar;472(3):976-82
pubmed: 24078171
J Bone Joint Surg Am. 1981 Feb;63(2):244-8
pubmed: 7007391
BMC Musculoskelet Disord. 2015 Nov 26;16:369
pubmed: 26612576
J Hosp Infect. 1997 Mar;35(3):215-22
pubmed: 9093920
Indian J Orthop. 2013 May;47(3):295-301
pubmed: 23798762
Biomaterials. 2005 Nov;26(33):6477-86
pubmed: 15992923
Orthop Surg. 2012 Aug;4(3):139-44
pubmed: 22927147
Sci Rep. 2017 May 11;7(1):1736
pubmed: 28496119
World J Surg. 2008 Jun;32(6):952
pubmed: 18401640
J Orthop Traumatol. 2016 Dec;17(4):377-382
pubmed: 27394916
Orthopedics. 2013 Feb;36(2):e216-22
pubmed: 23380017
Spine (Phila Pa 1976). 1989 Dec;14(12):1324-31
pubmed: 2617362
Indian J Orthop. 2013 Nov;47(6):645-6
pubmed: 24379478
Int J Oral Maxillofac Surg. 2006 Aug;35(8):708-13
pubmed: 16690249
J Biomed Mater Res B Appl Biomater. 2004 Aug 15;70(2):209-17
pubmed: 15264302
Am J Orthop (Belle Mead NJ). 2012 Jan;41(1):20-3
pubmed: 22389890
J Neurol Neurosurg Psychiatry. 2011 Aug;82(8):e3
pubmed: 21386107
BMC Musculoskelet Disord. 2012 Jul 29;13:134
pubmed: 22839754
Orthop Traumatol Surg Res. 2022 Jun;108(4):102966
pubmed: 34033919
Acta Orthop. 2009 Feb;80(1):4-8
pubmed: 19234881
ANZ J Surg. 2013 Jul;83(7-8):564-70
pubmed: 22925525